B-cell lymphoma, unclassifiable, (BCLU) is a subtype of lymphoma first recognized by the World Health Organization in 2008. Patients with this lymphoma have a very poor prognosis, with a rapidly progressive and refract...
老年弥漫大 B 细胞淋巴瘤患者一线应用塞利尼索方案的疗效与安全性:一项真实世界研究 《BMC Cancer》:Efficacy and safety of selinexor-based regimens as first-line treatments for elderly patients with diffuse large B-cell lymphoma: a real-world study 编辑推荐: 为探讨塞利尼索(selinexor)方案用于老年弥漫大 ...
Patients with aggressive B-cell lymphoma have many new options for treatment, including chimeric antigen receptor (CAR) T cell therapies like axicabtagene ciloleucel (Yes Carta) and lisocabtagene maraleucel (Breyanzi), antibody drug conjugates, and cellular therapies. ...
You may wonder about the impact on your long-term health if you delay treatment. But studies show that for people with slow-growing types of B-cell lymphoma, there is no difference in the way the disease develops between immediate treatment and watchful waiting. As long as you get regular ...
B-cell lymphomas come in many types. Some grow quickly and others grow slowly. Your doctor will explain which type you have and how to treat it. Large B-cell lymphoma The most common type of non-Hodgkin's lymphoma is called diffuse large B-cell lymphoma (DLBCL). One in three people wi...
Sonali Smith, MD, discusses T-cell–directed therapies for indolent B-cell lymphoma, focusing on their efficacy, FDA-approved treatments, and treatment challenges, such as managing cytokine release syndrome.Pharmacy Times interviewed Sonali Smith, MD, chief of the Section of Hematology/Oncology at Un...
Tafasitamab Plus Lenalidomide Versus 3 Rituximab Based Treatments for Non-Transplant Eligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Matching-Adjusted Indirect Comparison 文章来源:Adv Ther,IF:4.070 原文链接:https://pubmed.ncbi....
13. Jinchul Kim et al. Comparison of Several Salvage Treatments of Relapsed/Refractory Large B-Cell Lymphoma Including Chimeric Antigen Receptor T-Cell Therapy: A Systematic Review and Meta‐Analysis. 2022ASH .Abstr #2986 14. Sujitha K...
The identification of new druggable targets and better-tolerated treatments for aggressive lymphomas are therefore much needed. While B-cell receptor (BCR) signaling is essential for normal B-cell function, it is often deregulated and provides critical pro-survival signals for B-cell lymphomagenesis ...
Researchers at the National Institutes of Health (NIH) have developed a non-chemotherapy treatment regimen that is achieving full remissions for some people with aggressive B-cell lymphoma that has come back or is no longer responding to standard treatments. The five-drug combination targets multiple...